These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 33533892

  • 1. Emerging views of statin pleiotropy and cholesterol lowering.
    Yu D, Liao JK.
    Cardiovasc Res; 2022 Jan 29; 118(2):413-423. PubMed ID: 33533892
    [Abstract] [Full Text] [Related]

  • 2. Strategies to Overcome Residual Risk During Statins Era.
    Cho KI, Yu J, Hayashi T, Han SH, Koh KK.
    Circ J; 2019 Sep 25; 83(10):1973-1979. PubMed ID: 31391351
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May 25; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression-Brief Report.
    Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G.
    Arterioscler Thromb Vasc Biol; 2018 Jan 25; 38(1):262-265. PubMed ID: 29122815
    [Abstract] [Full Text] [Related]

  • 8. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML, Perrone V, Veronesi C, Degli Esposti L, Andretta M, Plebani M, Fadini GP, Vigili de Kreutzenberg S, Avogaro A.
    Cardiovasc Diabetol; 2021 Jul 16; 20(1):144. PubMed ID: 34271920
    [Abstract] [Full Text] [Related]

  • 9. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N, Tocci G, Ferri C.
    High Blood Press Cardiovasc Prev; 2018 Mar 16; 25(1):5-7. PubMed ID: 29305812
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Statins.
    Ratchford EV, Martin SS.
    Vasc Med; 2017 Oct 16; 22(5):442-445. PubMed ID: 28803537
    [No Abstract] [Full Text] [Related]

  • 12. Implications for REDUCE IT in clinical practice.
    Bittner V.
    Prog Cardiovasc Dis; 2019 Oct 16; 62(5):395-400. PubMed ID: 31715195
    [Abstract] [Full Text] [Related]

  • 13. Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
    Zhang X, Xing L, Jia X, Pang X, Xiang Q, Zhao X, Ma L, Liu Z, Hu K, Wang Z, Cui Y.
    Cardiovasc Ther; 2020 Oct 16; 2020():3987065. PubMed ID: 32411300
    [Abstract] [Full Text] [Related]

  • 14. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
    Reynolds TM, Pottle A, Quoraishi SH.
    Vasc Health Risk Manag; 2021 Oct 16; 17():227-237. PubMed ID: 34054297
    [Abstract] [Full Text] [Related]

  • 15. Poststatin Lipid Therapeutics: A Review.
    Jia X, Lorenz P, Ballantyne CM.
    Methodist Debakey Cardiovasc J; 2019 Oct 16; 15(1):32-38. PubMed ID: 31049147
    [Abstract] [Full Text] [Related]

  • 16. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR.
    Am J Cardiovasc Drugs; 2010 Oct 16; 10 Suppl 1():10-7. PubMed ID: 21391729
    [Abstract] [Full Text] [Related]

  • 17. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.
    Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC.
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr 01; 6(2):115-121. PubMed ID: 31873726
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.